News

NERVIANO, IT March 1st 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Anders Elm Pedersen MD, PhD, DMSc., has joined Global Clinical Development as Senior Medical Director to lead the clinical strategy and clinical development plans of the Company’s ever-growing pipeline. Anders brings extensive research, clinical development and medical affairs experience to NMS, and authored more than 80 research publications within preclinical and clinical research .
(Click the title for the complete article)

01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Gergely Balint, MSc, has joined the Global Asset Leadership Team to lead the development and maximize the value of its MPS1 Inhibitor Asset, NMS-01940153E (NMS-153).
(Click the title for the complete article)

January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor Asset, NMS-173, and facilitate its expanding and advancing clinical pipeline. Terrence West, MBA, joins as New Business, Virtual CEO.
(Click the title for the complete article)

MPS1 Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer

The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). The study findings were reported at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
(Click the title for the complete article)

NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership Team and Chief of Staff, will take primary responsibility for accelerating groupwise operational performance, continuing the transformation of the business model of each subsidiary and implementing the strategic vision and values of the company, in collaboration with leaders across the firm in her new role as COO.
(Click the title for the complete article)

A week from the presentation of Nerviano Medical Sciences S.r.l. (a member of NMS Group) on NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, we’re thrilled to share the official press release from ENA 2022 of NMS-153. A highly potent and selective inhibitor of the MPS1 kinase, NMS-153 is a mitotic regulator frequently overexpressed and activated in cancer. NMS-153 showed a broad preclinical activity in different tumor types, including HCC. Please read the press release here! 
(Click the title for the complete article)

NMS today announced that Salvatore Marengoni Galdy, M.D., has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. Dr. Galdy will drive values of our assets through planning and leading the clinical development to meet all time, quality, budget, Company standards and scientific requirements.
(Click the title for the complete article)

Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today shared data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) in an oral presentation by Dr. Maria Reig at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  in Barcelona.
(Click the title for the complete article)

Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  which will be held October 26-28, 2022 at the CCIB in Barcelona.
(Click the title for the complete article)

NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) will be reported in an oral presentation by Dr. Maria Reig at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  which will be held October 26-28, 2022 at the CCIB in Barcelona.
(Click the title for the complete article)